These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33367900)

  • 1. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
    Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
    Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
    Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
    Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
    Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries.
    Glintborg B; Di Giuseppe D; Wallman JK; Provan SA; Nordström D; Hokkanen AM; Österlund J; Kristianslund E; Kvien TK; Gudbjornsson B; Hetland ML; Michelsen B; Jacobsson L; Askling J; Lindström U
    Rheumatology (Oxford); 2023 Feb; 62(2):647-658. PubMed ID: 35723604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
    Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
    Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
    Xu Y; Li Y; Dong M; Gao Z; Chen X; Liu H; Shen M
    Rheumatology (Oxford); 2020 Dec; 59(12):3657-3665. PubMed ID: 33038239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
    Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
    Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
    Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
    Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment.
    Ørnbjerg LM; Brahe CH; Linde L; Jacobsson L; Nissen MJ; Kristianslund EK; Santos MJ; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Barcelos A; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; Mann H; Pavelka K; van de Sande M; van der Horst-Bruinsma IE; Suarez MP; Sánchez-Piedra C; Macfarlane GJ; Iannone F; Michelsen B; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Joint Bone Spine; 2024 Jul; 91(4):105729. PubMed ID: 38582359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
    Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
    Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
    Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
    Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of TNF-α inhibition
    Elliott A; Wright G; Pendleton A; Rooney M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
    Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L
    Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab: A Review in Psoriatic Arthritis.
    Blair HA
    Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis.
    Jiménez-Morales A; Cáliz R; Aceituno S; Prades M; Blanch C
    Reumatol Clin (Engl Ed); 2021 Nov; 17(9):536-542. PubMed ID: 34756316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.